[go: up one dir, main page]

IL138345A - Composition comprising eprosartan and its use in the preparation of medicaments for blocking angiotensin ii receptors and for treating hypertension, congestive heart failure and renal failure - Google Patents

Composition comprising eprosartan and its use in the preparation of medicaments for blocking angiotensin ii receptors and for treating hypertension, congestive heart failure and renal failure

Info

Publication number
IL138345A
IL138345A IL13834599A IL13834599A IL138345A IL 138345 A IL138345 A IL 138345A IL 13834599 A IL13834599 A IL 13834599A IL 13834599 A IL13834599 A IL 13834599A IL 138345 A IL138345 A IL 138345A
Authority
IL
Israel
Prior art keywords
eprosartan
composition
preparation
salt
medicament
Prior art date
Application number
IL13834599A
Other languages
English (en)
Other versions
IL138345A0 (en
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of IL138345A0 publication Critical patent/IL138345A0/xx
Publication of IL138345A publication Critical patent/IL138345A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
IL13834599A 1998-03-11 1999-03-11 Composition comprising eprosartan and its use in the preparation of medicaments for blocking angiotensin ii receptors and for treating hypertension, congestive heart failure and renal failure IL138345A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7766098P 1998-03-11 1998-03-11
PCT/US1999/004651 WO1999045779A1 (en) 1998-03-11 1999-03-11 Novel compositions of eprosartan

Publications (2)

Publication Number Publication Date
IL138345A0 IL138345A0 (en) 2001-10-31
IL138345A true IL138345A (en) 2004-12-15

Family

ID=22139347

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13834599A IL138345A (en) 1998-03-11 1999-03-11 Composition comprising eprosartan and its use in the preparation of medicaments for blocking angiotensin ii receptors and for treating hypertension, congestive heart failure and renal failure

Country Status (21)

Country Link
EP (1) EP1061803B1 (zh)
JP (1) JP2002506010A (zh)
KR (1) KR20010041796A (zh)
CN (1) CN1299235A (zh)
AT (1) ATE508633T1 (zh)
AU (1) AU757547B2 (zh)
BR (1) BR9908691A (zh)
CA (1) CA2323363C (zh)
CY (1) CY1111738T1 (zh)
CZ (1) CZ303067B6 (zh)
DK (1) DK1061803T3 (zh)
ES (1) ES2366394T3 (zh)
HU (1) HU228574B1 (zh)
IL (1) IL138345A (zh)
NO (1) NO331207B1 (zh)
NZ (1) NZ506700A (zh)
PL (1) PL192545B1 (zh)
SI (1) SI1061803T1 (zh)
TR (1) TR200002646T2 (zh)
WO (1) WO1999045779A1 (zh)
ZA (1) ZA991922B (zh)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4990696A (en) 1995-02-24 1996-09-11 Nanosystems L.L.C. Aerosols containing nanoparticle dispersions
WO2000004862A2 (en) * 1998-07-20 2000-02-03 Smithkline Beecham Corporation Bioenhanced formulations comprising eprosartan in oral solid dosage form
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
BR0110079A (pt) * 2000-04-12 2002-12-31 Novartis Ag Combinação de compostos orgânicos
DE10230272A1 (de) * 2002-07-05 2004-01-22 Solvay Pharmaceuticals Gmbh AT1-Rezeptorantagonisten zur Prävention von Folgeschlaganfällen
EP1382334A1 (en) * 2002-07-11 2004-01-21 Université de Picardie Jules Verne Use of angiotensin II AT1-receptor blockers (ARB), alone or combined with thiazide or angiotensin II for the treatment of stroke
CA2513729A1 (en) * 2003-01-21 2004-08-05 Ranbaxy Laboratories Limited Co-precipitated amorphous losartan and dosage forms comprising the same
KR20120058618A (ko) 2003-01-31 2012-06-07 다이이찌 산쿄 가부시키가이샤 동맥 경화 및 고혈압증의 예방 및 치료를 위한 의약
BRPI0512379A (pt) * 2004-06-23 2008-03-11 Solvay Pharm Gmbh composições farmacêuticas compreendendo inibidores de nep, inibidores do sistema de produção de endotelina endógena e antagonista do receptor at1
US20060099230A1 (en) * 2004-11-10 2006-05-11 Chin-Chih Chiang Novel formulations of eprosartan with enhanced bioavailability
WO2006136916A2 (en) * 2005-06-20 2006-12-28 Glenmark Pharmaceuticals Limited Substantially pure micronized particles of telmisartan and pharmaceutical compositions containing same
KR100715355B1 (ko) * 2005-09-30 2007-05-07 주식회사유한양행 프란루카스트를 함유하는 분무-건조 과립 및 그의 제조방법
EP2181109A4 (en) * 2007-07-25 2011-08-03 Hetero Drugs Ltd CRYSTALLINE PARTICLES OF EPROSARTAN MESYLATE AND PROCESS FOR PREPARING PURE EPROSARTAN
EP2108365A1 (en) * 2008-04-09 2009-10-14 LEK Pharmaceuticals d.d. Single dosage pharmaceutical formulation comprising eprosartan mesylate
CN103705510A (zh) * 2013-12-27 2014-04-09 华润赛科药业有限责任公司 一种阿齐沙坦固体组合物的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) * 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
JPS587609B2 (ja) 1979-06-17 1983-02-10 フロイント産業株式会社 粉体薬剤のコ−テング法
DE3013839A1 (de) * 1979-04-13 1980-10-30 Freunt Ind Co Ltd Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
US5185351A (en) * 1989-06-14 1993-02-09 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
JP2642486B2 (ja) 1989-08-04 1997-08-20 田辺製薬株式会社 難溶性薬物の超微粒子化法
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
CZ293345B6 (cs) * 1996-03-29 2004-04-14 Smithkline Beecham Corporation Dihydrát monomethansulfonatu kyseliny (E)-alfa-[2-n-butyl-1-[(4-karboxyfenyl)methyl]-1H-imidazol-5-yl]methylen-2-thiofenpropionové
CZ296274B6 (cs) * 1997-08-06 2006-02-15 Smithkline Beecham Corporation Neutralizacní komplex arginyl-eprosartan, zpusob jeho prípravy a prostredek

Also Published As

Publication number Publication date
CA2323363A1 (en) 1999-09-16
AU757547B2 (en) 2003-02-27
CN1299235A (zh) 2001-06-13
EP1061803A4 (en) 2007-12-26
EP1061803B1 (en) 2011-05-11
CA2323363C (en) 2008-09-30
KR20010041796A (ko) 2001-05-25
PL192545B1 (pl) 2006-11-30
CY1111738T1 (el) 2015-10-07
NZ506700A (en) 2003-03-28
CZ20003288A3 (cs) 2001-03-14
HU228574B1 (en) 2013-04-29
EP1061803A1 (en) 2000-12-27
HUP0101243A1 (hu) 2002-05-29
JP2002506010A (ja) 2002-02-26
ATE508633T1 (de) 2011-05-15
BR9908691A (pt) 2000-12-26
ZA991922B (en) 1999-09-13
CZ303067B6 (cs) 2012-03-21
TR200002646T2 (tr) 2001-01-22
HUP0101243A3 (en) 2005-09-28
ES2366394T3 (es) 2011-10-19
AU2890999A (en) 1999-09-27
SI1061803T1 (sl) 2011-09-30
WO1999045779A1 (en) 1999-09-16
NO331207B1 (no) 2011-10-31
PL343411A1 (en) 2001-08-13
NO20004502D0 (no) 2000-09-08
DK1061803T3 (da) 2011-08-29
IL138345A0 (en) 2001-10-31
NO20004502L (no) 2000-11-07

Similar Documents

Publication Publication Date Title
EP1039909B1 (en) Method of production and composition of an oral preparation of itraconazole
CA2338256C (en) Bioenhanced formulations comprising eprosartan in oral solid dosage form
JP2022510732A (ja) ニロチニブの医薬組成物
US20020098241A1 (en) High drug load immediate and modified release oral dosage formulations and processes for their manufacture
EP1061803B1 (en) Compositions of eprosartan
EP0889880B1 (en) Eprosartan dihydrate and a process for its production and formulation
KR20160113294A (ko) 안드로겐 수용체 길항제의 고체 제약 조성물
EA015108B1 (ru) Способ получения твердой фармацевтической композиции, содержащей валсартан
KR101931489B1 (ko) 칼슘 길항약／안지오텐신 ｉｉ 수용체 길항약 함유 의약 제제의 제조 방법
CA2310028C (en) High drug load immediate and modified release oral dosage formulations and processes for their manufacture
US20030022928A1 (en) Novel compositions of eprosartan
JP6141580B2 (ja) ラノラジンおよびドロネダロンの医薬組成物
US11260055B2 (en) Oral pharmaceutical composition of lurasidone and preparation thereof
JP2009538905A (ja) 感湿性薬物を含んで成る安定性製剤及びその製造方法
MXPA00008888A (en) Novel compositions of eprosartan
ZA200406553B (en) Pharmaceutical compositions comprising 2-(4-ethoxy-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazoloÄ1,5-bÜpyridazine in nanoparticulate form.
MXPA00006574A (en) Method and composition of an oral preparation of itraconazole

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees